BioSpace News Archive

Sage Therapeutics today announced that the Company will present at the Canaccord 38th Annual Growth Conference on Wednesday, August 8, 2018 at 11:00 A.M. ET in Boston, MA.

Promising Technology Platform to Potentially Deliver Therapies to Treat a Broad Spectrum of Ophthalmic Diseases.

LivaNova PLC reported results for the quarter ended June 30, 2018.

BD (Becton, Dickinson and Company) appointed Simon Campion as executive vice president of BD and president, BD Interventional segment, effective Sept. 4.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134.

Presented Data from Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Overall Response Rate of 83% and Durable Ongoing Reponses up to 22 Months

REGENXBIO Inc. announced that it will host a conference call on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2018 and recent operational highlights.

Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investigational, once-daily norepinephrine and serotonin reuptake inhibitor (NSRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH).

AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston.

Conference call scheduled today at 9:00 a.m. ET